Rethinking Clinical Trials

DECEMBER 12, 2023

Their work included insights from the Coordinating Center and Core Working Groups , analyses from the Distributed Research Network , and study designs and results from the NIH Collaboratory Trials.

Trials 141

Trials Clinical Trials Clinical Trials Nurses 141

Rethinking Clinical Trials

OCTOBER 24, 2022

The NIH Pragmatic Trials Collaboratory is pleased to announce the addition of 2 new Core Working Groups that will be focused on implementation science and health equity. The Implementation Science Core will be co-led by Devon Check and Hayden Bosworth. From left, Devon Check, PhD, and Hayden Bosworth, PhD.

Trials 100

Trials Nurses Clinical Research Research 100

Rethinking Clinical Trials

AUGUST 16, 2022

Patrick Heagerty to reflect on the role of the Biostatistics and Study Design Core Working Group in helping the Demonstration Project teams design trial and analyze the data, and to discuss their focus for the Core’s future contributions to pragmatic clinical trials.

Research 130

Research Development Trials Clinical Trials 130

Rethinking Clinical Trials

JANUARY 3, 2024

She is a longtime member of the NIH Pragmatic Trials Collaboratory's Biostatistics and Study Design Core Working Group. The session will be held on Friday, January 5, at 1:00 pm eastern. She is also an associate professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health.

Trials 286

Trials Clinical Trials Clinical Trials Medicine 286

Rethinking Clinical Trials

AUGUST 1, 2023

If you are active on LinkedIn, we invite you to follow our page for the latest news about our innovative Demonstration Projects, tools and resources from the Core Working Groups, upcoming sessions of our weekly Rethinking Clinical Trials Grand Rounds webinar series, and fresh content from the Living Textbook of Pragmatic Clinical Trials.

Clinical Trials 130

Clinical Trials Clinical Trials Research Trials 130

Rethinking Clinical Trials

JUNE 13, 2023

We’re in for some challenging times, and I can’t think of a better group [than the NIH Collaboratory] to figure out how to navigate those challenges,” said Curtis. In hearing about several cross-Core collaborations during the meeting, a new era for the program became evident.

Trials 130

Trials Clinical Trials Clinical Trials Research 130

Scienmag

MAY 9, 2022

COVID-19 has disrupted financial statement auditing globally and impacted group dynamics in an industry vital to the health of the economy, according to a new study.

62

62

Rethinking Clinical Trials

JUNE 29, 2022

Most of the study teams were able to work closely with healthcare system partners to adapt their study interventions. Most of the study teams were able to work closely with healthcare system partners to adapt their study interventions. Trial delays often created statistical challenges, especially for those using stepped-wedge designs.

Trials 100

Trials Clinical Trials Clinical Trials Research 100

XTalks

APRIL 24, 2024

In my country, Canada, according to the Government of Canada’s website “Social, economic and political factors shape the conditions in which individuals grow, live, work and age, and are vitally important for health and wellbeing. In 1914, Booker T. We all need to close the gap.

Research 105

Research Allergies Clinical Trials Clinical Trials 105

pharmaphorum

MARCH 15, 2022

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias.

Development 111

Development Pharma Companies Clinical Trials Clinical Trials 111

XTalks

OCTOBER 4, 2023

She has worked both in country-level and global roles, working on all components of core market access areas: health economics, access strategy, pricing, government affairs and patient advocacy.

Marketing 105

Marketing Development Drugs Gene Therapy 105

pharmaphorum

FEBRUARY 8, 2022

Now, healthcare companies have a unique opportunity to continue this momentum beyond the pandemic bubble as Healthware Group CEO Roberto Ascione tells Dr Paul Tunnah at the 2021 Frontiers Health conference in Milan. For Healthware Group CEO Roberto Ascione, this transition has been a long time coming.

Medicine 72

Medicine Doctors Doctor 72

Rethinking Clinical Trials

JUNE 30, 2022

It’s helpful to have the sounding board of regular contact with principal investigators and research teams grappling with often similar issues that arise in implementing pragmatic trials (Steering Committee meetings, annual meetings, and Core Working Groups). What challenges have you faced, and how have you dealt with them?

Trials 169

Trials Clinical Trials Clinical Trials Clinical Research 169

The Pharma Data

APRIL 1, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Company Limited (“TCHC”) to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group Inc. This divestment agreement was first announced in August 2020.

Sales 52

Sales Production Branding Medicine 52

pharmaphorum

DECEMBER 22, 2020

A core aim of the ATSTN is to develop National Training Centres to deliver specialist on-site courses, including innovative digital training utilising virtual reality, providing learners with the hands-on expertise and experience to succeed in the advanced therapies and vaccine manufacturing sector.

Gene Therapy 88

Gene Therapy Manufacturing Gene Vaccination 88

pharmaphorum

FEBRUARY 1, 2022

Core themes will include: Reimbursement and payer models. Core themes will include: Reimbursement and payer models. If you are a patient or patient advocate, or work in another sector that may be entitled to a discounted or free ticket, please email us directly at info@rwelive.com to let us know. BOOK YOUR PLACE. Pricing. .

Big Data 59

Big Data Regulation 59

pharmaphorum

MAY 31, 2022

Equity, diversity, and inclusion (ED&I) strategies in the UK’s pharma sector are beginning to take shape, but there is still much work to be done. The drive to address health inequalities, understand unmet needs, and diversify clinical trials is a core focus for our members.”. And what more needs to be done? Progress report.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Research 95

pharmaphorum

SEPTEMBER 18, 2020

Vertex is already the top player in CF with a quartet of exon-skipping medicines that tackle the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that underlies the disease, but there are still a sizeable group of patients with no treatment options.

Gene Editing 105

Gene Editing Gene Vaccination Vaccine 105

pharmaphorum

NOVEMBER 11, 2021

Fishawack Health, the leading commercialization partner for the life science industry, welcomes FIDE to its group—an independent expert-led consultancy specializing in chronic inflammatory skin conditions and offering independent expert insight from leading dermatologists. November 10, 2021, UK.

Dermatology 98

Dermatology Life Science Marketing Production 98

pharmaphorum

MAY 20, 2021

Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. But future success is at risk if we do not create a culture that inspires and supports the next generation of researchers, says a report from the Russell Group of universities. Job security.

Research 100

Research Production Vaccination Vaccine 100

pharmaphorum

AUGUST 2, 2022

Indeed, one of the main barriers to treating these diseases is that a high proportion of patients are part of marginalized groups that are difficult to reach through traditional healthcare systems. Anthony Martinez (Tony), a member of the International Hepatitis Education Program (IHEP), has worked in this field for 18 years.

Pharma Companies 105

Pharma Companies Doctors Doctor Drugs 105

pharmaphorum

SEPTEMBER 21, 2022

This manifested itself in two ways, she tells pharmaphorum: “More than 90% of people said patient centricity was core to their business. There has been much progress in recent years, with companies increasingly working with patient advocacy groups (PAGs) to gather insights and implement projects. And that is driving change.”.

Development 98

Development Regulation Drugs Production 98

pharmaphorum

JUNE 9, 2022

It already boasts a team of 75 experts and will recruit additional staff in areas like digital product management, full stack development and data science, it added, working with the Women In Tech non-profit group to close the gender gap in its workforce.

Manufacturing 105

Manufacturing Clinical Trials Clinical Trials Medicine 105

Bioengineer

JULY 19, 2021

In this study, Matthias Drosten, Marina Salmón and Guillem Paniagua of the Experimental Oncology Programme, headed by Mariano Barbacid at the CNIO, had a more fundamental goal: to understand how the isoforms work separately. These findings suggest that for therapies to be effective, they must be targeted at both gene products. Credit: CNIO.

Research 52

Research Gene Genetic Engineering Genetics 52

XTalks

AUGUST 3, 2023

To support this effort, Xtalks has established the Pharmacovigilance Peer Circle — a working group of senior-level professionals in this area — for which Raphael Pareschi will be the chairperson. Pharmacovigilance is an essential and dynamic clinical discipline that holds tremendous importance in supporting public health.

Regulation 97

Regulation Marketing Life Science Drugs 97

The Pharma Data

FEBRUARY 22, 2022

The Chairman thanked Carole Piwnica for her contribution to the transformation of the group during her almost 12 years in office, and Melanie Lee for her contribution to the scientific reorientation of the group and the creation of the Scientific Committee. In 2013, she was appointed Finance Director of the Artémis Group.

Medicine 52

Medicine DNA Development Clinical Trials 52

The Pharma Data

OCTOBER 26, 2021

Q3 core¹ operating income grew +9% (cc, +10% USD) Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Sandoz declined -15% (cc, -13% USD), impacted by gross margin Q3 operating income grew +32% (cc, +34% USD) Q3 net income increased +41% (cc, +43% USD) Q3 free cash flow 1 of USD 4.4

Medicine 52

Medicine Sales Marketing Generic Pharmaceutical 52

pharmaphorum

AUGUST 18, 2022

But that doesn’t mean the work of organisations like the Digital Therapeutics Alliance (DTA) is done. There is still a lot of work to be done in digital therapeutics to standardise and harmonise DTx efforts, and that’s something else Coder expects to see underway at Frontiers as DTx players gather in person in Milan. Far from it.

Regulation 98

Regulation Marketing Production Branding 98

Pharmaceutical Technology

NOVEMBER 4, 2022

At the core of health innovation in Scotland is the collaboration between industry, academia, and government. At the core of health innovation in Scotland is the collaboration between industry, academia, and government. PMS-IC is funded by the Scottish Funding Council and Scottish Enterprise. We act a bit like an introduction agency.

Medicine 130

Medicine Development Research Gene 130

pharmaphorum

MAY 26, 2021

Digital health player Akili has raised $110 million fourth-round funding, backed by a number of pharma groups, as it works towards extending its product range beyond its flagship EndeavorRx app. Akili is one of a group of companies that were founded by PureTech Health, which retains a controlling stake.

Production 66

Production Development Research 66

pharmaphorum

MARCH 4, 2021

AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approaches that only work for specific populations. Because of this, there are increasing calls for ‘AI Equity’ to be promoted across the industry. “AI

Life Science 106

Life Science Genetics Development Research 106

The Pharma Data

NOVEMBER 17, 2021

Still, there’s work to do to optimize the entire food, feed, energy and fiber value chain and its use of the precious natural coffers needed to power the earth while icing broader sweats to combat climate change. Bayer will also resettle its digital husbandry core capabilities to the new structure for its own client- facing results.

Branding 52

Branding Development Manufacturing Production 52

pharmaphorum

MARCH 10, 2022

Biologics have revolutionised treatments for several serious diseases, some of which had no therapeutic alternatives until now,” says Antonio Magnelli, head of the Chiesi Group’s Global Manufacturing Division. In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs.

Production 98

Production Life Science Development Gene Therapy 98

pharmaphorum

SEPTEMBER 20, 2021

COVID-19 has fundamentally changed much of our lives – from how we interact with people to how we work. Now, as the healthcare industry begins to define its ‘new normal’ in a post-COVID world, is it time to re-examine which strategies work, why, and what comes next for the future of pharma sampling. Personalisation is Key.

Sales 98

Sales Marketing Pharma Companies Licensing 98

Drug Discovery World

JUNE 29, 2023

Kate Woolland, Chief Operating Officer, Closed Loop Medicine Bringing extensive strategic business experience, including over 13 years in healthcare, Kate will play a pivotal role in leading collaboration across the multi-disciplinary team whilst working closely with current and future commercial partners.

Drugs 52

Drugs Gene Therapy Development Clinical Trials 52

pharmaphorum

NOVEMBER 4, 2022

“I am very much looking forward to working with my new colleagues and to continue transforming lives for generations.” “I am very much looking forward to working with my new colleagues and to continue transforming lives for generations.”

In-Vivo 59

In-Vivo Gene Therapy Doctors Doctor 59

pharmaphorum

SEPTEMBER 16, 2021

Since their inception in 2013, Clinical Commissioning Groups (CCGs) have led medicines optimisation efforts at local level. This is important work given the scale of the challenge. Half of all UK adults take at least one prescribed medicine and 30-50% of the medicines prescribed for long-term conditions are not taken as intended.

Medicine 113

Medicine Pharmacy Development 113